Anika Therapeutics Raises Lower End of Full-Year Revenue Guidance
Story updates
12:07:00 PM UTC
SquawkNews
Revenue Increased 10% Year Over Year, Led by 17% Commercial Channel Growth Including More Than 30% Growth in IntegrityTM RevenueSecured New 10-Year Hyvisc® Partnership with Enhanced Economics; Reintroduced Hyaff Non-Orthopedic OEM ProductRaised Lower End of Full-Year 2026 Total Company Revenue Guid…
12:07:01 PM UTC
SquawkNews
Anika Therapeutics reported Q3 2026 revenue of $30.6M, up 10% from $27.8M a year earlier. The company raised the lower end of 2026 revenue guidance and raised adjusted EBITDA guidance; it reaffirmed 2027 revenue guidance.Material DetailsContext by AI AnalystThis is a quarterly update showing ongoin…